Welcome to our dedicated page for Equillium SEC filings (Ticker: EQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Equillium, Inc. (Nasdaq: EQ) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Equillium is a clinical-stage biotechnology company based in La Jolla, California, focused on developing immunomodulatory therapies for severe autoimmune and inflammatory disorders, with its lead candidate EQ504 targeting the aryl hydrocarbon receptor (AhR).
Through this page, users can review Form 10-Q and 10-K reports, which include details on Equillium’s operating losses, cash resources, going concern language from auditors, and management’s discussion of risks and plans related to its immuno-inflammatory pipeline and financing needs. Form 8-K filings document material events such as private placement agreements to fund EQ504 development, amendments to at-the-market sale agreements, changes in independent registered public accounting firms, leadership and board updates, and the termination of collaboration and license agreements related to itolizumab with Biocon Limited.
Equillium’s filings also cover Nasdaq listing matters, including notices of non-compliance with minimum bid price requirements and subsequent confirmation of regained compliance. Additional disclosures describe the company’s adoption of a cryptocurrency treasury reserve strategy, amendments to its investment policy, and supplemental risk factors associated with digital asset holdings.
On Stock Titan, these documents are updated in near real time as they appear on EDGAR. AI-powered summaries help explain complex sections, highlight key points on topics such as EQ504 development plans, capital structure changes, and treasury strategy, and make it easier to identify items like equity issuances, open market sale agreements and auditor changes. Users can also quickly locate Form 4 and other ownership-related filings to track insider and major holder activity as it is reported.
Equillium, Inc. senior vice president and COO Christine Zedelmayer exercised stock options and sold shares in a planned transaction. On March 9, 2026 she exercised options for a total of 152,361 shares of common stock at an exercise price of $0.785 per share.
The same day she sold 181,219 shares of common stock at a weighted average price of $2.00 per share, with individual sale prices ranging from $2.00 to $2.015, under a Rule 10b5-1 trading plan adopted on August 27, 2025. After these transactions she directly owned 62,586 shares of Equillium common stock.
Christine Zedelmayer reported sales of common stock under Rule 144. The filing lists four transactions dated 11/25/2025, 12/12/2025, 12/15/2025, and 02/19/2026 totaling 229,739 shares sold for aggregate proceeds of $377,658.
The transactions are reported on Form 144 and reflect dispositions from stock option-related and employee plan holdings referenced in the securities table.
Equillium, Inc. executive Christine Zedelmayer reported option exercises and related share sales in a Form 4. On February 19, 2026, she exercised employee stock options covering 109,375 and 76,562 shares, converting them into common stock at stated exercise prices.
On the same date, she sold 109,375 shares at $1.7814 per share and 76,562 shares at $1.7406 per share in open-market transactions. The filing states these sales were made under a Rule 10b5-1 trading plan adopted on August 27, 2025. After these transactions, she directly owned 191,444 shares of Equillium common stock.
EQ reported insider sales via Form 144 by Christine Zedelmayer. The filing lists multiple reported dispositions of Common Stock on 11/25/2025 (8,098 shares, $7,696.00), 12/12/2025 (23,804 shares, $31,897.00), 12/15/2025 (11,900 shares, $15,589.00), and 12/23/2025 (100,000 shares, $150,000.00).
The filing also lists planned sales of Common Stock issuable upon exercise of stock options dated 01/12/2022 (109,375 shares) and 01/02/2024 (76,562 shares), with sale method indicated as Cash.
Janus Henderson Group plc has filed an amended Schedule 13G reporting beneficial ownership of 6,083,239 shares of Equillium, Inc. common stock, representing 9.99% of the class. These holdings are managed through various affiliated asset managers on behalf of client accounts, called Managed Portfolios.
The position includes shares that may be obtained through exercise of certain pre-funded warrants that are exercisable within 60 days, but only to the extent total beneficial ownership does not exceed 9.99% of Equillium’s outstanding common stock. An additional 18,584,856 warrants are excluded from the reported figures due to this ownership cap. Dividends and sale proceeds belong to the Managed Portfolios, not Janus Henderson.
Equillium, Inc. granted its President and Chief Scientific Officer, Stephen Connelly, an employee stock option to buy 1,150,000 shares of common stock at an exercise price of $1.31 per share on 01/07/2026. The option has an expiration date of 01/06/2036 and was received at no cost, as reflected by a derivative security price of $0.
According to the vesting terms, 25% of the shares under the option vest on the first anniversary of the vesting commencement date, with the remaining shares vesting in 36 equal monthly installments over the following three years. After this grant, Connelly beneficially holds 1,150,000 stock options directly.
Equillium, Inc. reported that Sr. Vice President and COO Christine Zedelmayer received an employee stock option grant on 01/07/2026. The derivative award covers 500,000 stock options with an exercise price of $1.31 per share, allowing her to buy common stock at that price in the future. The grant was reported at a cost of $0 for the option itself and leaves her with 500,000 derivative securities beneficially owned directly after the transaction.
According to the vesting terms, 25% of the option vests on the first anniversary of the vesting commencement date, and the remaining options vest in 36 equal monthly installments over the following three years, resulting in a standard four-year vesting schedule tied to ongoing service.
Equillium, Inc. reported that its Chief Executive Officer, director and 10% owner, Bruce D. Steel, was granted an employee stock option on 01/07/2026. The option covers 1,750,000 shares of common stock at an exercise price of $1.31 per share and expires on 01/06/2036. According to the vesting terms, 25% of the shares vest on the first anniversary of the vesting commencement date, with the remaining shares vesting in 36 equal monthly installments over the following three years. After this grant, Steel beneficially holds 1,750,000 derivative securities directly.
Equillium, Inc. Principal Accounting Officer Tom Penny reported one stock sale and a new stock option grant. Penny sold 6,533 shares of common stock on January 8, 2026 at $1.29 per share, leaving him with no shares of common stock held directly after the sale. The filing notes these sales were made under a Rule 10b5-1 trading plan adopted on October 10, 2025, meaning they were pre‑scheduled rather than discretionary.
On January 7, 2026, Penny was granted an employee stock option to purchase 450,000 shares of Equillium common stock at an exercise price of $1.31 per share. The option vests over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining shares vesting in 36 equal monthly installments over the following three years. After this grant, he holds 450,000 stock options directly.
An employee shareholder of EQ has filed a notice of proposed sale on Form 144 to sell 6,533 shares of common stock. The shares are to be sold through Maxim Group, with an aggregate market value of $8,427.00, on the NASDAQ, with an approximate sale date of 01/08/2026. These shares were acquired on 06/18/2024 under an Employee Stock Purchase Plan from the issuer and were paid for in cash on 12/12/2025. The company had 60,893,283 shares of common stock outstanding at the time referenced in the notice.